OBJECTIVES: The oscillation model of Parkinson disease (PD) states that, in the subthalamic nucleus (STN), increased θ (4-10 Hz) and β (11-30 Hz) frequencies were associated with worsening whereas γ frequencies (31-100 Hz) were associated with improvement of motor symptoms. However, the peak STN frequency in each band varied widely from subject to subject. We hypothesized that STN deep brain stimulation (DBS) at individualized γ frequencies would improve whereas θ or β frequencies would worsen PD motor signs. METHODS: We prospectively studied 13 patients with PD. STN local field potential (LFP) was recorded after electrode implantations, in the OFF and then in ON dopaminergic medication states while patients performed wrist movements. Six individual peak frequencies of the STN LFP power spectra were obtained: the greatest decrease in θ and β and greatest increase in γ frequencies in the ON state (MED) and during movements (MOVE). Eight DBS frequencies were applied including 6 MED and MOVE frequencies, high frequency (HF) used for chronic stimulation, and no stimulation. The patients were assessed using the motor Unified Parkinson's Disease Rating Scale (mUPDRS). RESULTS: STN DBS at γ frequencies (MED and MOVE) and HF significantly improved mUPDRS scores compared to no stimulation and both γ frequencies were not different from HF. DBS at θ and β frequencies did not worsen mUPDRS scores compared to no stimulation. CONCLUSION: Short-term administration of STN DBS at peak dopamine-dependent or movement-related γ frequencies were as effective as HF for reducing parkinsonian motor signs but DBS at θ and β frequencies did not worsen PD motor signs. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that STN DBS at patient-specific γ frequencies and at usual high frequencies both improved mUPDRS scores compared to no stimulation and did not differ in effect.
OBJECTIVES: The oscillation model of Parkinson disease (PD) states that, in the subthalamic nucleus (STN), increased θ (4-10 Hz) and β (11-30 Hz) frequencies were associated with worsening whereas γ frequencies (31-100 Hz) were associated with improvement of motor symptoms. However, the peak STN frequency in each band varied widely from subject to subject. We hypothesized that STN deep brain stimulation (DBS) at individualized γ frequencies would improve whereas θ or β frequencies would worsen PD motor signs. METHODS: We prospectively studied 13 patients with PD. STN local field potential (LFP) was recorded after electrode implantations, in the OFF and then in ON dopaminergic medication states while patients performed wrist movements. Six individual peak frequencies of the STN LFP power spectra were obtained: the greatest decrease in θ and β and greatest increase in γ frequencies in the ON state (MED) and during movements (MOVE). Eight DBS frequencies were applied including 6 MED and MOVE frequencies, high frequency (HF) used for chronic stimulation, and no stimulation. The patients were assessed using the motor Unified Parkinson's Disease Rating Scale (mUPDRS). RESULTS: STN DBS at γ frequencies (MED and MOVE) and HF significantly improved mUPDRS scores compared to no stimulation and both γ frequencies were not different from HF. DBS at θ and β frequencies did not worsen mUPDRS scores compared to no stimulation. CONCLUSION: Short-term administration of STN DBS at peak dopamine-dependent or movement-related γ frequencies were as effective as HF for reducing parkinsonian motor signs but DBS at θ and β frequencies did not worsen PD motor signs. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that STN DBS at patient-specific γ frequencies and at usual high frequencies both improved mUPDRS scores compared to no stimulation and did not differ in effect.
Authors: F Alonso-Frech; I Zamarbide; M Alegre; M C Rodríguez-Oroz; J Guridi; M Manrique; M Valencia; J Artieda; J A Obeso Journal: Brain Date: 2006-05-09 Impact factor: 13.501
Authors: Moran Weinberger; Neil Mahant; William D Hutchison; Andres M Lozano; Elena Moro; Mojgan Hodaie; Anthony E Lang; Jonathan O Dostrovsky Journal: J Neurophysiol Date: 2006-09-27 Impact factor: 2.714
Authors: Lars Timmermann; Lars Wojtecki; Joachim Gross; Ralph Lehrke; Jürgen Voges; Mohammed Maarouf; Harald Treuer; Volker Sturm; Alfons Schnitzler Journal: Mov Disord Date: 2004-11 Impact factor: 10.338
Authors: David Williams; Marina Tijssen; Gerard Van Bruggen; Andries Bosch; Angelo Insola; Vincenzo Di Lazzaro; Paolo Mazzone; Antonio Oliviero; Angelo Quartarone; Hans Speelman; Peter Brown Journal: Brain Date: 2002-07 Impact factor: 13.501
Authors: P Limousin; P Pollak; A Benazzouz; D Hoffmann; J F Le Bas; E Broussolle; J E Perret; A L Benabid Journal: Lancet Date: 1995-01-14 Impact factor: 79.321
Authors: Chiung Chu Chen; Wey Yil Lin; Hsiao Lung Chan; Po Hsun Tu; Shih Tseng Lee; Chin Song Lu; Peter Brown Journal: Exp Brain Res Date: 2013-03-30 Impact factor: 1.972
Authors: Christos Sidiropoulos; Richard Walsh; Christopher Meaney; Y Y Poon; Melanie Fallis; Elena Moro Journal: J Neurol Date: 2013-06-09 Impact factor: 4.849
Authors: David T Brocker; Brandon D Swan; Rosa Q So; Dennis A Turner; Robert E Gross; Warren M Grill Journal: Sci Transl Med Date: 2017-01-04 Impact factor: 17.956
Authors: Zachary J Conway; Peter A Silburn; Wesley Thevathasan; Karen O' Maley; Geraldine A Naughton; Michael H Cole Journal: Mov Disord Clin Pract Date: 2018-11-08